Genenta Science S.p.A.
GNTA · Biological Products, (No Diagnostic Substances) · EDGAR filings ↗
Grade
D50Pre-revenue clinical-stage gene-therapy biotech with a long cash runway but negative returns and an unproven pivot into a defense/aerospace 'Golden Power' consolidator.
Strengths
- Strong runway (16.4 quarters, 88th pct) and pristine liquidity (current/quick ratio ~14) on €28M cash
- Loss narrowed ~27% year over year as spend was contained
Risks
- No product revenue, negative ROE/ROA and recurring losses (€62.6M accumulated deficit); single licensed asset (Temferon) seeking a partner
- Speculative, never-attempted strategic transformation into an industrial consolidator adds execution and identity risk
Notable findings
- Cash burnNegative free cash flow (-8.1M)
- Notable holderHeld by 1 notable fund(s): CITADEL ADVISORS LLC (as of 2025-12-31)
Key metrics
Return on equity
-29.9%
Return on assets
-20.5%
Current ratio
14.2×
Free cash flow
-$8M
EBITDA
-$8M
Tangible book value
$26M
Cash & investments
$33M
Cash runway
16q
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-04-01 | 2025-12-31 | 0001493152-26-014387 ↗ |
| 20-F | 2025-03-28 | 2024-12-31 | 0001641172-25-001207 ↗ |
| 20-F | 2024-03-29 | 2023-12-31 | 0001493152-24-011999 ↗ |
| 20-F | 2023-04-21 | 2022-12-31 | 0001493152-23-013272 ↗ |
| 20-F | 2022-05-02 | 2021-12-31 | 0001493152-22-011671 ↗ |